|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM363404236 |
| 003 |
DE-627 |
| 005 |
20240119231912.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202306676
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1264.xml
|
| 035 |
|
|
|a (DE-627)NLM363404236
|
| 035 |
|
|
|a (NLM)37847869
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Cai, Ying
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Inhibiting Endothelial Cell-Mediated T Lymphocyte Apoptosis with Integrin-Targeting Peptide-Drug Conjugate Filaments for Chemoimmunotherapy of Triple-Negative Breast Cancer
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 19.01.2024
|
| 500 |
|
|
|a Date Revised 19.01.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Tumor-associated endothelial cells (TECs) limit antitumor immunity via inducing apoptosis of infiltrating T lymphocytes through a Fas ligand (FasL) mediated mechanism. Herein, this work creates a peptide-drug conjugate (PDC) by linking 7-ethyl-10-hydroxycamptothecin (SN38) to hydrophilic segments with either RGDR or HKD motif at their C-terminus through a glutathione-responsive linker. The PDCs spontaneously assemble into filaments in aqueous solution. The PDC filaments containing 1% of SN38-RGDR (SN38-HKD/RGDR) effectively target triple-negative breast cancer (TNBC) cells and TECs with upregulated expression of integrin, and induce immunogenic cell death (ICD) of tumor cells and FasL downregulation of TECs. SN38-HKD/RGDR increases infiltration, activity, and viability of CD8+ T cells, and thus inhibits the growth of primary tumors and pulmonary metastasis. This study highlights the synergistic modulation of cancerous cells and TECs with integrin-targeting PDC filaments as a promising strategy for TNBC chemoimmunotherapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Fas ligand
|
| 650 |
|
4 |
|a immunotherapy
|
| 650 |
|
4 |
|a peptide-drug conjugate
|
| 650 |
|
4 |
|a triple-negative breast cancer
|
| 650 |
|
4 |
|a tumor-associated endothelial cells
|
| 700 |
1 |
|
|a Zhu, Binyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shan, Xiaoting
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, Lingli
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sun, Xujie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xia, Anqi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Binhao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Yang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhu, Helen He
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Pengcheng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Yaping
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 3 vom: 22. Jan., Seite e2306676
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:3
|g day:22
|g month:01
|g pages:e2306676
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202306676
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 3
|b 22
|c 01
|h e2306676
|